The Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI) trial

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered	
12/02/2010		[X] Protocol	
Registration date	Overall study status	Statistical analysis plan	
17/02/2010	Ongoing	Results	
Last Edited	Condition category	[] Individual participant data	
07/03/2025	Circulatory System	[X] Record updated in last year	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Duncan J Stewart

Contact details

Ottawa Hospital General Campus Sprott Centre for Stem Cell Research 501 Smyth Road, Critical Care Wing - 5th Floor Room 5206 - Box 511 Ottawa Canada K1H 8L6 +1 613 737 8899 ext. 79017 djstewart@toh.ca

Type(s)

Scientific

Contact name

Ms Leslie Carlin

Contact details

Regenerative Medicine Clinical Research Ottawa Hospital Research Institute (OHRI) 1053 Carling Ave. Admin. Services Bldg, Rm 2-010, Box 693 Ottawa Canada K1Y 4E9 +1 (0)819 665 8477 lcarlin@ohri.ca

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

NCT00936819

Protocol serial number

MCT-90169

Study information

Scientific Title

Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction: a multicentre, phase IIb randomised placebo-controlled trial

Acronym

ENACT-AMI

Study objectives

The primary objectives of this study are to determine whether endothelial-like culture modified mononuclear cell (E-CMM) therapy is effective in improving cardiac function following acute myocardial infarction, and whether eNOS transfected E-CMMs are superior to non-transfected E-CMMs.

A secondary objective is to determine whether the efficacy of E-CMM therapy depends on the timing of cell therapy (5 - 10 days versus 11 - 30 days).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 11/11/2011, Health Canada (Biologics and Genetics Therapies Directorate, Address Locator #0701B, Ottawa, Ontario, K1A 0K9, Canada; +1 (0)613 863 8405; brdd.dgo.enquiries@hc. sc.gc.ca), ref: Control # 150429 / File # 9427-O0476-39C

Study design

Phase IIb double-blind parallel randomized placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute myocardial infarction

Interventions

After providing informed consent, all participants who meet the eligibility criteria will undergo apheresis. Apheresis is performed to obtain mononuclear cells from the participant's blood. These cells are sent to a site-specific cell manufacturing lab where they will be processed according to the random allocation. The random allocation will be to:

- 1. Endothelial-like circulating mononuclear cells (E-CMMs)
- 2. E-CMMs transfected with human eNOS
- 3. Plasma-lyte A

Approximately 5 days later, the participant will receive the study treatment via intracoronary injection through the distal stent of the IRA during coronary angiography in the catheterisation suite. Study follow-up will include clinic visits the day after cell therapy, at 6 weeks, 3 and 6 months post-injection.

Intervention Type

Other

Phase

Phase II/III

Primary outcome(s)

Change in global left ventricular ejection fraction (LVEF) from baseline to 6 months after study treatment as determined by magnetic resonance imaging (MRI).

Key secondary outcome(s))

Changes from baseline to 6 months after study treatment of:

- 1. Regional wall motion, wall thickening and infarct volume as determined by cardiac MRI
- 2. Echocardiographic assessment of LVEF and ventricular volumes
- 3. Time to clinical worsening (death, hospitalisation for angina, reinfarction)
- 4. Quality of life (36-item short form health survey [SF-36] and Duke Activity Status Index [DASI] questionnaires)

Completion date

18/09/2029

Eligibility

Key inclusion criteria

- 1. Male or female 18 75 years of age
- 2. Clinical diagnosis of ST-elevation myocardial infarction (MI) of greater than 1 mm in two adjacent electrocardiogram (ECG) limb leads, or greater than 2 mm in two adjacent ECG precordial leads, or a new left bundle branch block and an increase in cardiospecific enzymes (creatine kinase [CK] greater than 3 x upper limit of normal [ULN]), and either positive myocardial bands (MB) fraction or increase in troponin compared to institutional laboratory

normal ranges

- 3. Patients who have suffered an acute Q-wave MI within the preceding 30 days prior to inclusion and have undergone percutaneous coronary intervention (PCI) with stent implantation in the infarct-related artery (IRA)
- 4. Culprit artery must have distal flow greater than thrombolysis in myocardial infarction (TIMI) 1
- 5. Left ventricular ejection fraction (LVEF) less than or equal to 45% by echocardiography (Simpson's Method) performed at least 2 days after onset of chest pain
- 6. In the case of previous MI, must have documentation of LVEF greater than 45% prior to index AMI
- 7. Females who are surgically sterile, or are post-menopausal, or have documented infertility, or are of child-bearing potential using one of the following methods of contraception:
- 7.1. Barrier-type devices (e.g., condom, diaphragm) used in combination with a spermicide; a double barrier method is recommended
- 7.2. Intrauterine devices (IUDs)
- 7.3. Oral or implanted contraceptives, if used in combination with a barrier method
- 8. Provided written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

75 years

Sex

Αll

Total final enrolment

47

Key exclusion criteria

- 1. Significant unprotected left main disease (greater than 50% stenosis) on diagnostic angiography
- 2. Planned coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) for a coronary stenosis greater than 70% in the non-infarct related artery (IRA)
- 3. History of sustained ventricular arrhythmias not related to AMI (evidenced by previous holter monitoring +/- medication history for sustained ventricular arrhythmias in the subject's medical chart
- 4. History of cerebrovascular accident or transient ischaemic attack less than or equal to 6 months
- 5. Any exclusion to magnetic resonance imaging (MRI) (includes already implanted automatic internal defibrillator or permanent pacemaker). Recent stent implantation is NOT an exclusion to MRI.

- 6. Persistent haemodynamic instability (need for ongoing pharmacological or mechanical support greater than 24 hours of the onset of chest pain)
- 7. Mechanical ventilatory support
- 8. Significant cardiac valvular disease
- 9. Left ventricular (LV) dysfunction from any other cause (e.g., non-ischaemic cardiomyopathy, collagen diseases)
- 10. Clinical evidence of persistent heart failure not responding to standard oral therapy
- 11. Clinical evidence of persistent ischaemia at time of cell therapy
- 12. Current pregnancy or nursing mothers
- 13. Known history of human immunodeficiency virus (HIV)
- 14. Known history of hepatitis B or C (hepatitis B surface antigen [HBsAg], hepatitis B [HB] core, hepatitis C [HC] antibody)
- 15. History of untreated ethanol (ETOH) or drug abuse
- 16. Creatinine clearance less than 60 by Cockcroft-Gault calculator (SI units)
- 17. Contraindications to apheresis (inadequate venous access or haematological exclusions)
- 18. Evidence of active infection
- 19. Significant co-morbidity (e.g., immunocompromise, hepatic failure)
- 20. Known history of malignancy in the past 5 years (except for low-grade and fully resolved non-melanoma skin cancer)
- 21. Known allergy to gentamycin and amphotericin
- 22. Patients receiving other investigational drug or device therapy within 30 days of screening
- 23. Patients who have received gene therapy
- 24. Inability ot provide informed consent and comply with the follow-up visit schedule

Date of first enrolment

01/05/2010

Date of final enrolment

15/09/2019

Locations

Countries of recruitment

Canada

Study participating centre Ottawa Hospital General Campus

Ottawa Canada K1H 8L6

Sponsor information

Organisation

Ottawa Hospital Research Institute (OHRI) (Canada)

ROR

https://ror.org/03c62dg59

Organisation

Canadian Stem Cell Network

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (ref: MCT-90169)

Alternative Name(s)

Instituts de Recherche en Santé du Canada, Canadian Institutes of Health Research (CIHR), CIHR_IRSC, Canadian Institutes of Health Research | Ottawa ON, CIHR - Welcome to the Canadian Institutes of Health Research, CIHR, IRSC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Canada

Results and Publications

Individual participant data (IPD) sharing plan

Current IPD sharing plan as of 07/03/2025:

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Duncan Stewart (djstewart@toh.ca).

The de-identified raw data and clean data set files are housed in OHRI's securely encrypted password-protected Sharepoint folder system and will be maintained there for at least 15 years following trial completion.

Prior to implementing any requests for data sharing (other than from the REB pre-approved ENACT AMI Study team) that are received and approved by Dr Stewart, a Secondary Use of Information Application will be completed and submitted to the OHSN-REB for approval to share data/files. Each of the participants will be approached with a separate signed consent

obtained for permission to share their de-identified data. As required, a Data Sharing Agreement will be signed and executed between Dr Stewart and the requesting party prior to any data being shared with that party.

Previous IPD sharing plan:

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Duncan Stewart (djstewart@toh.ca).

The de-identified raw data and clean data set files are housed in OHRI's securely encrypted password-protected Sharepoint folder system and will be maintained there for 15 years following trial completion.

Prior to implementing any requests for data sharing (other than from the REB pre-approved ENACT AMI Study team) that are received and approved by Dr Stewart, a Secondary Use of Information Application will be completed and submitted to the OHSN-REB for approval to share data/files. Each of the participants will be approached with a separate signed consent obtained for permission to share their de-identified data. As required, a Data Sharing Agreement will be signed and executed between Dr Stewart and the requesting party prior to any data being shared with that party.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added Peer reviewed	Patient-facing?
Protocol article	protocol	01/03/2010	11/04/2019 Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025 No	Yes